Slide 1: Q4 and Year End 2023 Earnings and Business Update Call
Q4 and Year End 2023 Earnings and Business Update Call March 26, 2024 Syelalelae MedTech Evidence Based Healing
Slide 2: Disclaimers
Sanara MedTech s. Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company,” “Sanara,” "we," ‘our’ or “us’). A
Slide 3: Executive Summary
» Sanara MedTech Executive Summary + Financial Update + Highest net revenue quarter and year in the Company's history ($17.7 million in Q4 and $65.0 million in 2023). + Net loss of $0.3 million in Q4 and $4.4 million for the year. + Breakeven on an Adjusted EBITDA“ basis in Q4 and slightly negative
Slide 4: 2023 Key Strategic and Operational Achievements
Sanara MedTech 2023 Key Strategic and Operational Achievements CellerateRX/Collagen Products Acquisition — Acquired rights for key products and eliminated royalties to sellers. ALLOCYTE® Plus Launch - First sale in Q4 and the Company believes it has adequate inventory on hand. BIASURGE® Launch - Fir
Slide 5: Surgical Sales
Sanara MedTech Surgical Sales Sales Overview (Unaudited) + Sanara products were sold in over 1,000 hospitals/ASCs across 34 states plus the District of Columbia‘) in the TTM + Sanara products were contracted or approved to be sold in more than 3,000 hospitals/ASCs as of December 31, 2023 + BIASURGE®
Slide 6: Tissue Health Plus
Sanara MedTech Tissue Health Plus Tissue Health Plus Update + We are seeking partners to facilitate commercialization of Tissue Health Plus, our value-based care strategy for the chronic wound care market, and share in the development cost of the strategy. + Excluding noncash items, our full year op
Slide 7: FY 2023 Financial Highlights
Sanara MedTech FY 2023 Financial Highlights > Revenue + For the year ended December 31, 2023, we generated net revenues of $65.0 million compared to net revenues of $45.8 million in the previous year (a 42% year over year increase). + The higher net revenue for 2023 was primarily due to increased sa
Slide 8: FY 2023 Financial Highlights (continued)
FY 2023 Financial Highlights (continued) » Sanara MedTech R&D Expenses + R&D expenses for the year ended December 31, 2023, were $4.1 million compared to $3.4 million for the year ended December 31, 2022. + The higher R&D expenses in 2023 were primarily due to costs related to the Precision Healing
Slide 9: Questions
Questions Syelalelae MedTech Evidence Based Healing
Slide 10: Appendix
Appendix Syelalelae MedTech Evidence Based Healing
Slide 11: Non-GAAP Financial Measure
ie Bgnara Non-GAAP Financial Measure Use of Non-GAAP Financial Measure To supplement the Company's financial information presented in accordance with generally accepted accounting principles in the United States ((GAAP"), we present certain non-GAAP financial measures in this press release and on th
Slide 12: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures Reconciliation of GAAP to Non-GAAP Financial Measures Reconciliation of Net Loss to Adjusted EBITDA (Unaudited) Net Loss Adjustments Interest expense and other Income tax benefit Depreciation and amortization. ‘Noncash share-based compensation Ch